Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the US marketing authorization in November 2022. In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Drug: IberdomideBiological: Belantamab MafodotinDrug: DexamethasoneProcedure: EchocardiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT06232044
- Locations
- 🇺🇸
Mary Greeley Medical Center, Ames, Iowa, United States
🇺🇸McFarland Clinic - Ames, Ames, Iowa, United States
🇺🇸McFarland Clinic - Boone, Boone, Iowa, United States
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.